MetaVia Inc. (MTVA)
| Market Cap | 8.99M -37.3% |
| Revenue (ttm) | n/a |
| Net Income | -13.13M |
| EPS | -4.79 |
| Shares Out | 5.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 593,153 |
| Open | 1.880 |
| Previous Close | 2.010 |
| Day's Range | 1.720 - 2.170 |
| 52-Week Range | 0.966 - 19.029 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 19.33 (+1,010.92%) |
| Earnings Date | May 14, 2026 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 rece... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MTVA stock is "Buy." The 12-month stock price target is $19.33, which is an increase of 1,010.92% from the latest price.
News
MetaVia Transcript: Emerging Growth Conference 93
Recent conference presentations highlighted strong safety and PK data for DA-1726 and promising combination results for vanoglipol, especially with resmetirom and metformin. Cash reserves are expected to last through ongoing clinical trials into Q4.
MetaVia Transcript: AGM 2026
Five key proposals were presented, including director elections, auditor ratification, a reverse stock split, and an equity plan amendment. All proposals were approved, with voting results to be filed with the SEC.
MetaVia presents data at ADA supporting DA-1726, vanoglipel
MetaVia (MTVA) announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Association’s 2026 Scientific Sessions, held June ...
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Wei...
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim...
MetaVia’s DA-1726 shows efficacy in obesity and MASH presentations
MetaVia (MTVA) announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin – OXM – analog agonist targeting glucagon-like peptide-1 receptors, or GLP1R, and glucagon receptor...
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau Exploratory FibroScan Assessments Demonstrated Early Liver-Related Improvements Ongoing Phase 1 Part 3...
3 Penny Stocks to Watch Now, 5/21/26
HCW Biologics ($HCWB), MetaVia ($MTVA), and Silexion Therapeutics ($SLXN) are the three penny stocks to watch on May 21, according to TipRanks’ Penny Stock Screener tool. Penny stocks refer to low-pri...
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication of ...
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Three Late-Breaking Posters Highlight DA-1726, a GLP-1/Glucagon Dual Agonist, and Vanoglipel, a GPR119 Agonist CAMBRIDGE, Mass., May 18, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-st...
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Key Milestone Achieved with Dosing of the First Pat...
MetaVia Earnings release: Q1 2026
MetaVia released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
MetaVia Quarterly report: Q1 2026
MetaVia has published its Q1 2026 quarterly earnings report on May 14, 2026.
MetaVia Slides: Investor presentation
MetaVia has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breakin...
MetaVia Proxy statement: Proxy filing
MetaVia filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
MetaVia Proxy statement: Proxy filing
MetaVia filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
MetaVia says first patient dosed in Part 3 of Phase 1 trial of DA-1726
MetaVia (MTVA) announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and…
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: M...
MetaVia: Cash position adequate to fund operations into 4Q26
Cash and cash equivalents were $10.3M as of December 31, 2025, compared with $16M as of December 31, 2024. With these funds and proceeds from the January 2026 public offering,…
MetaVia CEO says ‘significant progress advancing our cardiometabolic portfolio’
“We made significant progress advancing our cardiometabolic portfolio during the year, punctuated by the positive data, released in January of this year, from the Phase 1 extended 8-week, non-titrated...
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration Study to Ev...
MetaVia Annual report: Q4 2025
MetaVia has published its Q4 2025 annual report on March 26, 2026.
MetaVia Earnings release: Q4 2025
MetaVia released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
MetaVia Slides: Investor presentation
MetaVia has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.